Amporin Pharmaceuticals receives CHF 150,000
Summary
Three months following its incorporation, Amporin Pharmaceuticals has won the third stage of Venture Kick, winning itself CHF 150,000 investment to develop amyloid pore inhibitors, a breakthrough class of small-molecule drugs to treat deadly degenerative diseases.Over 50 deadly degenerative diseases, including Alzheimers, Parkinsons, type II diabetes, and many rare neurodegenerative disorders, are linked to protein misfolding and aggregation. These diseases collectively affect over half a billion people and kill 3.6 million people annually, costing society USD 3 trillion per year. Currently, there is no effective treatments to halt or reverse the progressive degeneration that ultimately leads to death.Amporin Pharmaceuticals aims to develop a new class of small-molecule drugs that block and eliminate toxic soluble oligomers and pores from within cell membranes. The company plans to develop and license the first effective acute oral disease-modifying treatments for up to six major diseases, with an initial focus on Parkinsons and ALS (amyotrophic lateral sclerosis).Parkinsons disease alone affects around 1 million people in the US and 10 million people globally. The current global drug market for Parkinsons disease is about USD 6 billion per year, with a potential market of USD 15 billion per year for the first effective disease-modifying treatments.Using the CHF 150,000 from Venture Kick, the Basel-based startup will establish its core operations and build a complete in vitro data package to validate and demonstrate the unique advantages of its technology to potential investors and licensing partners.Founded in April 2024, Amporins founding team includes CEO Dr. Kelvin Stott, CSO Dr. Herv\xe9 Schaffhauser, and CMO Prof. Daniel Umbricht, each with over 20 years of CNS drug development and R&D leadership experience in multiple Big Pharma companies, as well as biotech startups.Venture Kick has been a critical source of support in helping us to build a world-class company around a world-changing technology, highlighted Kelvin Stott, Amporin Pharmaceuticals Co-Founder and CEO.